HURA TuHURA Biosciences, Inc.
Debt Financing ·
TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million.
Parkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026.
TuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.
The company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.
TuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.
The draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031.
TuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender.
TuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral.
The $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes.
Four investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.
TuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.
Each Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.
The letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $20.5 million | $13.3 million |
| Net income (loss) | -$30.1 million | -$21.7 million |
| Cash from operations | -$27.6 million | -$14.7 million |
| Cash and equivalents | $3.6 million | $12.7 million |
Our latest story on this, dated Jun 30, 2025: "TuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share". The story links the filing or release it is based on. Read the story.
TuHURA Biosciences, Inc. trades under the ticker HURA on NASDAQ.
TuHURA Biosciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PL3; LS:A3EWMJ; LSX:A3EWMJ.
The SEC Central Index Key (CIK) for TuHURA Biosciences, Inc. is 1498382. Its filings are on SEC EDGAR.
63,726,617 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records TuHURA Biosciences, Inc. under United States.
Our directory classifies TuHURA Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for TuHURA Biosciences, Inc. is US8989201038.
aibio.space lists TuHURA Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
TuHURA Biosciences, Inc. reported a net loss of $30.1 million for the fiscal year ended Dec 31, 2025, and used $27.6 million of cash in operations, per its annual report to the SEC.
$20.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$995,977 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on TuHURA Biosciences, dated Oct 9, 2026: "TuHURA Biosciences draws $650,000 more on Parkview credit line". TuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.07,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio